WASHINGTON, Nov 15 (Reuters) - Novartis AG's (NOVN.VX: Quote, Profile, Research) (NVS.N: Quote, Profile, Research) randomized clinical trial for its transplant drug Certican does not prove the proposed regimen is safe and effective, U.S. Food and Drug Administration staff said in a report released on Tuesday.
